secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001641172-25-016064
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve reverse split up to 1:199, authorized shares to 500M, and new equity plan
--------------------------------------------------------------------------------

- All five director nominees elected; advisory vote on executive compensation passes with 5.56M for, 0.11M against.
- Reverse stock split authorized in range of 1-for-2 to 1-for-199 over two years; 6.94M for, 0.54M against.
- Authorized common shares increased from 250M to 500M; 6.91M for, 0.57M against.
- 2025 Equity Incentive Plan approved with 5.39M for, 0.28M against, 1.81M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000164117225016064/0001641172-25-016064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000164117225016064/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer